Table 2.
Toxicity and Efficacy
| Overall | G-B | G-CHOP | P | |
|---|---|---|---|---|
| Induction therapy | ||||
| Thrombocytopenia any grade | 29 (25.4%) | 19 (31.1%) | 10 (20.4%) | 0.204 |
| Thrombocytopenia gr. 3–4– | 2 (1.8%) | 1 (1.6%) | 1 (2%) | 1.000 |
| Anemia any grade | 33 (29.5%) | 17 (28.8%) | 16 (32.7%) | 0.666 |
| Anemia gr. 3 –4 | 1 (0.9%) | 1 (1.7%) | 0 (0%) | 1.000 |
| Neutropenia any grade | 53 (46.5%) | 27 (44.3%) | 24 (49%) | 0.622 |
| Neutropenia gr. 3–4– | 33 (28.9%) | 15 (24.6%) | 17 (34.7%) | 0.246 |
| Infections any grade | 34 (31.2%) | 15 (26.3%) | 18 (37.5%) | 0.219 |
| Infections gr. 3–4– | 15 (13.8%) | 8 (14%) | 6 (12.5%) | 0.818 |
| Hospitalization due to AE | 20 (17.5%) | 10 (16.4%) | 9 (18.4%) | 0.785 |
| IgG levels after induction (g/L) | 7.3 ± 2.1 | 7.6 ± 2.5 | 7.1 ± 1.6 | 0.261 |
| Response after induction | 0.046a | |||
| CR | 78 (68.4%) | 39 (63.9%) | 39 (79.6%) | |
| PR | 29 (25.4%) | 16 (26.2%) | 10 (20.4%) | |
| PD | 2 (1.8%) | 1 (1.6%) | 0 | |
| Nonrelapse death | 3 (2.6%) | 3 (4.9%) | 0 | |
| Response not evaluated | 2 (1.8%) | 2 (3.3%) | 0 | |
| Infection at any time any grade | 47/114 (19.1%) | 23/61 (26.2%) | 22/49 (13.6%) | 0.559 |
| Infection at any time gr. 3–4 | 24/114 (10.1%) | 13/61 (14.3%) | 9/49 (6.8%) | 0.812 |
| Response at last follow-up | ||||
| Remission | 99 (86.8%) | 50 (82.0%) | 47 (95.9%) | |
| Progression | 6 (5.3%) | 3 (4.9%) | 2 (4.1%) | 1.000 |
| Nonrelapse death | 9 (7.9%) | 8 (13.1%) | 0 | 0.008a |
aStatistically significant at level P < 0.05.
AE = adverse event; CHOP = CVP + doxorubicine; CR = complete response; CVP = cyclophosphamide, vincristine and glucocorticoid; PD = progressive disease; PR = partial response.